FDA Approves Dapagliflozin (Farxiga) for Low-EF Heart Failure FDA Approves Dapagliflozin (Farxiga) for Low-EF Heart Failure
The widely anticipated approval makes dapagliflozin (Farxiga, AstraZeneca) the only drug in its class to be indicated for heart failure in the absence of diabetes.FDA Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news
More News: AstraZeneca | Cardiology | Dapagliflozin | Diabetes | Endocrinology | Forxiga | Heart | Heart Failure